Literature DB >> 2784065

Evidence that large granular lymphocytes from B-CLL patients with hypogammaglobulinemia down-regulate B-cell immunoglobulin synthesis.

N E Kay1, R T Perri.   

Abstract

B-chronic lymphocytic leukemia (CLL) patients frequently suffer from moderate to severe hypogammaglobulinemia. This complication is a serious cause of morbidity and mortality in this disorder. There is recent evidence that natural killer (NK) cells modulate B-cell immunoglobin (Ig) synthesis/secretion. The authors therefore evaluated the circulating NK cells from B-CLL patients on their ability to regulate mitogen-induced B-cell Ig synthesis. Blood, NK cells (CD16+, CD3-) from three B-CLL patients with hypogammaglobulinemia were able to clearly down-regulate the pokeweed mitogen (PWM)-induced-B-cell Ig secretion. In contrast, CD16+, CD3- cells from age-sex-matched controls or B-CLL patients with normal Ig were either nonregulatory or enhanced mitogen-induced B-cell Ig secretion. An alternative explanation for hypogammaglobulinemia in B-CLL patients is the immunomodulation of B-cell Ig production/secretion by CD16+, CD3- blood cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784065

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma.

Authors:  A Winkelstein; P S Jordan
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

2.  Specificity of G alpha q and G alpha 11 gene expression in platelets and erythrocytes. Expressions of cellular differentiation and species differences.

Authors:  G J Johnson; L A Leis; P C Dunlop
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

3.  Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells.

Authors:  A Cerutti; E C Kim; S Shah; E J Schattner; H Zan; A Schaffer; P Casali
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

4.  Experimental treatment of chronic lymphocytic leukemia with extracorporeal photochemotherapy. Initial observations.

Authors:  R M Knobler; R Pirker; E M Kokoschka; H Ludwig; W Linkesch; M Micksche
Journal:  Blut       Date:  1990-04

5.  Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Clare Sun; Xin Tian; Yuh Shan Lee; Sreenivasulu Gunti; Andrew Lipsky; Sarah E M Herman; Dalia Salem; Maryalice Stetler-Stevenson; Constance Yuan; Lela Kardava; Susan Moir; Irina Maric; Janet Valdez; Susan Soto; Gerald E Marti; Mohammed Z Farooqui; Abner L Notkins; Adrian Wiestner; Georg Aue
Journal:  Blood       Date:  2015-09-03       Impact factor: 22.113

Review 6.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

7.  Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.

Authors:  L E Robertson; A W Denny; Y O Huh; W Plunkett; M J Keating; J A Nelson
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 8.  Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic.

Authors:  Petra Langerbeins; Barbara Eichhorst
Journal:  Acta Haematol       Date:  2021-02-25       Impact factor: 2.195

9.  Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review.

Authors:  Ewelina Grywalska; Monika Zaborek; Jakub Łyczba; Rafał Hrynkiewicz; Dominika Bębnowska; Rafał Becht; Barbara Sosnowska-Pasiarska; Jolanta Smok-Kalwat; Marcin Pasiarski; Stanisław Góźdź; Jacek Roliński; Paulina Niedźwiedzka-Rystwej
Journal:  Cells       Date:  2020-11-02       Impact factor: 6.600

Review 10.  Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?

Authors:  Clare Sun; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-26       Impact factor: 2.861

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.